2022
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Journal Of The National Cancer Institute 2022, 114: 1619-1627. PMID: 36053203, PMCID: PMC9745425, DOI: 10.1093/jnci/djac163.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaSquamous cell carcinomaClinical trialsCell carcinomaTrial designTP53 mutationsNational Clinical Trials NetworkMetastatic disease settingsClinical trial developmentClinical Trials NetworkNovel therapeutic approachesNational Cancer InstituteMetastatic headTP53-mutated tumorsWorse outcomesClinical studiesFrequent genetic eventTherapeutic approachesCancer InstituteTrial developmentBreakout groupsPatientsDisease settingsBiomarker integrationTrials Network
2019
Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling
Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head & Neck 2019, 41: 1928-1934. PMID: 30758123, PMCID: PMC6542589, DOI: 10.1002/hed.25634.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerComprehensive genomic profilingThyroid cancerGenomic alterationsGenomic profilingMedian patient ageAggressive thyroid cancerYears of agePotential therapeutic significanceUnique mutation patternsDifferent molecular pathwaysATC specimensPatient ageCommon genomic alterationsKRAS alterationsCancer-related genesBRAF V600ETherapeutic significanceCancerBRAFMolecular pathwaysPatientsMutation patternsNumber alterationsNRASAPOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma
Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal NKS, Grandis JR, Yarbrough WG, Burtness B, Anderson KS, Townsend JP. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene 2019, 38: 3475-3487. PMID: 30647454, PMCID: PMC6499643, DOI: 10.1038/s41388-018-0657-6.Peer-Reviewed Original ResearchConceptsPositive selectionCancer phenotypeStrong positive selectionIntensity of selectionEffects of mutationsBasis of mutationsSomatic genetic variantsSomatic evolutionNeutral driftMutational processesAPOBEC mutagenesisBiochemical experimentsSelection intensityMolecular understandingCytosine basesIndividual substitutionsAPOBEC3B proteinMutant stateMutational signaturesGenetic variantsNeck squamous cell carcinomaMutationsE545KGene variantsPhenotype
2017
NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis
Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nature Communications 2017, 8: 1772. PMID: 29176703, PMCID: PMC5701248, DOI: 10.1038/s41467-017-01877-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesFemaleGene Expression Regulation, NeoplasticHistone MethyltransferasesHistone-Lysine N-MethyltransferaseHumansIntracellular Signaling Peptides and ProteinsLaryngeal NeoplasmsMaleMiddle AgedMutationNuclear ProteinsPrognosisRepressor ProteinsSquamous Cell Carcinoma of Head and NeckConceptsUseful clinical metricSquamous cell carcinomaLaryngeal cancer patientsPoor overall survivalIndependent validation cohortDistinct prognostic outcomesMolecular prognostic biomarkersOverall survivalCancer Genome AtlasFavorable prognosisBetter prognosisValidation cohortCell carcinomaCancer patientsLaryngeal tumorsLaryngeal cancerPrognostic outcomesTreatment stratificationPrognostic biomarkerNasal cavityOral cavityHigh recurrenceAnatomical sitesPatient stratificationCancer subtypesThe tumor genome in human immunodeficiency virus–related head and neck cancer: Exploitable targets?
Burtness B. The tumor genome in human immunodeficiency virus–related head and neck cancer: Exploitable targets? Cancer 2017, 124: 14-17. PMID: 29053184, DOI: 10.1002/cncr.31059.Peer-Reviewed Original Research
2014
Predicting survival in head and neck squamous cell carcinoma from TP53 mutation
Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, Forastiere AA, Koch WM, Chung CH, Karchin R. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Human Genetics 2014, 134: 497-507. PMID: 25108461, PMCID: PMC4324386, DOI: 10.1007/s00439-014-1470-0.Peer-Reviewed Original ResearchNew directions in perioperative management of locally advanced esophagogastric cancer.
Burtness B, Ilson D, Iqbal S. New directions in perioperative management of locally advanced esophagogastric cancer. American Society Of Clinical Oncology Educational Book 2014, e172-8. PMID: 24857100, DOI: 10.14694/edbook_am.2014.34.e172.Peer-Reviewed Original Research
2010
Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients
Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE. Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 358-365. PMID: 20086114, PMCID: PMC2846615, DOI: 10.1158/1055-9965.epi-09-0937.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCetuximabColorectal NeoplasmsErbB ReceptorsErlotinib HydrochlorideGefitinibHead and Neck NeoplasmsHumansKaplan-Meier EstimateLung NeoplasmsMass SpectrometryMutationProtein Kinase InhibitorsProteomicsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)QuinazolinesRas ProteinsSignal TransductionSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationConceptsCRC patientsColorectal cancerCancer patientsNon-small cell lung cancer patientsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsNon-small cell lung cancerRecurrent/metastatic headCell lung cancer patientsNeck squamous cell carcinomaLigand levelsReceptor tyrosine kinase inhibitorsCell lung cancerSquamous cell carcinomaLung cancer patientsKRAS mutation statusTyrosine kinase inhibitorsProteomic classificationSerum proteomic profilesDiverse cancer typesSite of originChemotherapy cohortMetastatic headPretreatment serumSurvival benefit
2003
Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.
Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E, Forastiere A. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clinical Cancer Research 2003, 9: 6461-8. PMID: 14695149.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBcl-2-Associated X ProteinCisplatinCombined Modality TherapyDisease-Free SurvivalDNA Mutational AnalysisErbB ReceptorsEsophageal NeoplasmsFemaleFluorouracilGenes, p53HumansImmunohistochemistryMaleMiddle AgedMutationProportional Hazards ModelsProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2Regression AnalysisTime FactorsTreatment OutcomeConceptsAdvanced esophageal cancerOverall survivalComplete responseEsophageal cancerEpidermal growth factor receptorP53 mutationsGrowth factor receptorClinical covariatesCellular markersBetter tumor differentiationPathological complete responseFactor receptorEGF-R expressionBcl-2 expressionInfusional cisplatinDaily radiotherapyMost patientsPoor OSPreoperative chemoradiotherapyPatient agePretreatment tumorOutcome predictorsPredictive factorsBarrett's metaplasiaTumor location